This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Will Neurocrine (NBIX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Neurocrine (NBIX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
3 Breakout Stocks of the Last Decade to Consider for 2020
by Christopher Vargas
The 2010s were a fruitful decade for investors as the S&P 500 has surged over 189% so far.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Neurocrine Biosciences (NBIX) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of 19.70% and 5.16%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Neurocrine Biosciences (NBIX)
by Zacks Equity Research
Neurocrine Biosciences (NBIX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CTLT vs. NBIX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CTLT vs. NBIX: Which Stock Is the Better Value Option?
Bet on Top-Notch Sector ETFs & Stocks to Sparkle Q4
by Sweta Killa
Investors could be well served by ETFs and stocks from sectors that house top-ranked industries.
Zoetis (ZTS) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
CTLT or NBIX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CTLT vs. NBIX: Which Stock Is the Better Value Option?
Buy These 7 Small Drugmakers to Boost Your Portfolio's Health
by Kinjel Shah
Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity have kept small drugmakers afloat in a competitive market.
HKMPF vs. NBIX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HKMPF vs. NBIX: Which Stock Is the Better Value Option?
Lannett (LCI) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Lannett (LCI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Is Neurocrine Biosciences (NBIX) a Great Growth Stock?
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Neurocrine Biosciences (NBIX).
Why Neurocrine (NBIX) Could Be Positioned for a Surge
by Zacks Equity Research
Neurocrine (NBIX) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
Moving Average Crossover Alert: Neurocrine Biosciences
by Zacks Equity Research
Neurocrine Biosciences, Inc. (NBIX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Spectrum Pharma's (SPPI) Loss Narrows in Q2, Stock Rises
by Zacks Equity Research
Spectrum Pharma (SPPI) beats bottom-line estimates in the second quarter.
Zoetis (ZTS) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Achillion (ACHN) Reports Wider Y/Y Loss in Q2, Revenues Nil
by Zacks Equity Research
Achillion (ACHN) meets bottom-line estimates in the second quarter. The absence of an approved product results in no revenues in the quarter.
Esperion (ESPR) Q2 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports mixed second-quarter results.
Jazz Pharma (JAZZ) Q2 Earnings and Sales Beat Estimates
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) reports encouraging second-quarter 2019 earnings and revenues and raises its sales guidance for 2019.
Why Neurocrine (NBIX) Might be Well Poised for a Surge
by Zacks Equity Research
Neurocrine (NBIX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of 54.17% and 14.59%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Neurocrine (NBIX) Ahead of Earnings?
by Zacks Equity Research
Neurocrine (NBIX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.